Main Pipeline

For Your Healthy Life, NovMetaPharma

Retroperitoneal Fibrosis Medication (NovRF)

Pipeline
NovRF
Program Target
Retroperitoneal Fibrosis
Patient Numbers
0.27 Million
Development Stage
Research
NovMetaPharma develops NovRF, a retroperitoneal fibrosis medication of first-in-class new substance.

The effect of inhibiting peritoneal EMT (epithelial-to-mesenchymal transition), peritoneal cell death, or immune cell invasion into the peritoneum has been confirmed with NovRF (retroperitoneal fibrosis medication) in an animal model in which retroperitoneal fibrosis was induced.

This confirms NovRF’s treatment effect for retroperitoneal fibrosis. Based on this, NovMetaPharma is conducting joint R&D to develop new retroperitoneal fibrosis prevention, improvement, and medication.

NovRF Development Status

01

Clinical Development Status
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
Substance: cGMP level

Preclinical

Clinical phase 1/2a

02

Patent Application and Registration Status
Patents IP Protection
Substance patent (US)
Application
2019
Registration
2020
Patent expiration (expected) year
2039
Retroperitoneal fibrosis prevention and treatment patent (KR)
Application·Registration
2020
Patent expiration (expected) year
2040